Agilent Technologies Inc (NYSE: A), a provider of analytical and clinical laboratory technology, announced on Monday that it played a key role in the FDA approval of AUCATZYL, Autolus Therapeutics' newly approved CAR T therapy.

The company's xCELLigence Real-Time Cell Analysis (RTCA) technology was instrumental in developing and validating the potency assay required for regulatory approval. By providing precise, real-time cell analysis without labels or dyes, the technology ensures accurate monitoring of cell behavior, improving reliability in drug development.

Executives from Agilent and Autolus will present insights on CAR T cell potency measurement at the 2025 Hybrid US Bioassay Conference in Tucson, Arizona, on 24-25 March 2025. The session, led by senior leaders from both companies, will highlight the role of cross-functional collaboration in advancing cell therapy development.

Agilent reported USD6.51bn in revenue for fiscal year 2024 and employs approximately 18,000 people worldwide.